• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$62.25 -$0.17 (-0.27%)

REAL-TIME: Last trade at

Abbott Laboratories

NYSE:ABT

Jump to this page for:

Related Resources

FDA Delays Abbott Laboratories's New Use for Top Drug Humira

5/23/2012 by BioSpace

Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight

5/23/2012 by PR Newswire

Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases

5/23/2012 by Zacks Investment Research

Global pharma

5/22/2012 by FT.com

Agilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company (A, DHR, ABT, AMGN, HOLX)

5/22/2012 by Investopedia

Abbott bid to expand Humira use in U.S. delayed, Dow Jones reports

5/22/2012 by Theflyonthewall.com

10 Market-Beating, Low-Beta Stocks

5/22/2012 by InvestorPlace

Tough Market? Not for Defensive Stocks

5/18/2012 by InvestorPlace

Leerink's medical supplies and devices analysts hold a conference call

5/17/2012 by Theflyonthewall.com

Abbott Labs is Cheaper Than You Think

5/17/2012 by InvestorPlace

Research and Markets: Abbott Enters into Licensing and Supply Agreement with Zydus Cadila

5/17/2012 by Business Wire

Abbott Helps Big Pharma Look Even Worse

5/16/2012 by TheStreet.com

Be Careful Chasing Higher Yielding Stocks

5/16/2012 by InvestorPlace

5 Triply Tempting Blue-Chip Stocks to Buy

5/16/2012 by InvestorPlace

Abbott Launches PediaSure SideKicks® Clear for Picky Eaters

5/16/2012 by PR Newswire

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb

5/15/2012 by PR Newswire

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases

5/15/2012 by Zacks Investment Research

In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018

5/15/2012 by PR Newswire

Abbott Xience Prime, V drug receives three-month duration indication in Europe

5/15/2012 by Theflyonthewall.com

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

5/15/2012 by PR Newswire

Bohuon clicks with Smith & Nephew

5/14/2012 by FT.com

Fraud: Abbott Labs To Pay $1.5 Billion To Resolve Charges Of Off-Label Drug Marketing

5/14/2012 by Chemical & Engineering News

Abbott Laboratories Escapes a Long-Running Consent Decree

5/10/2012 by BioSpace

Eli Lilly and Company and Abbott Laboratories Win Big in Sales Rep Overtime Case

5/10/2012 by BioSpace

Wasden Joins in Second Settlement with Abbott Laboratories

5/10/2012 by Pharmaceutical and Medical Packaging News

Whistle-blowers to split $84 million from Abbott Labs

5/10/2012 by The Columbus Dispatch - Columbus OH

Study: Manufacturing industry on rebound

5/9/2012 by Dayton Business Journal - Dayton OH

Tennnessee to get $5 million more in Abbott settlement

5/9/2012 by Memphis Business Journal - Memphis TN

Minnesota Connected to Abbott Labs’ Payment of $1.5 Billion to the Government in Fraud Case

5/8/2012 by PharmiWeb.com - UK

Abbott Laboratories Buys AP214 Hormone From Action Pharma for $110 Million

5/3/2012 by BioSpace

Abbott Laboratories Pins Hope on Consumer Products Post Split

5/3/2012 by BioSpace

St. Jude Medical, Abbott Laboratories expand marketing partnership

4/23/2012 by Minneapolis / St. Paul Business Journal - Minneapolis MN

Abbott Laboratories plant gets $2.2M in grants

4/9/2012 by Dayton Business Journal - Dayton OH